Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria
- PMID: 16280369
- DOI: 10.1093/ndt/gfi266
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria
Abstract
Background: The study was conducted in order to describe possible intraglomerular haemodynamic changes inducing proteinuria after 14 patients with chronic allograft dysfunction were converted from calcineurin inhibitors (CIs) to sirolimus without changing concomitant immunosuppression or antihypertensive treatment.
Methods: Creatinine, glomerular filtration rate (GFR), proteinuria, renal functional reserve (RFR) and effective renal plasma flow (ERPF) were determined before and 8 months after conversion. Intraglomerular pressure (P(G)), afferent arteriolar resistance (AAR) and efferent arteriolar resistance (EAR) were calculated using Gomez's formula.
Results: Creatinine (1.97 vs 2.075 mg/dl; P = 0.270) and GFR (40 vs 43 ml/min; P = 0.505) remained unchanged, proteinuria increased (338 vs 1146 mg/24 h; P = 0.006), RFR decreased (34.84 vs 13.47%; P = 0.019), ERPF (248 vs 310.6 ml/min; P = 0.0625) and P(G) (42.72 vs 46.17 mmHg; P = 0.0625) tendentially increased and AAR tendentially decreased (14.12 vs 10.28 dyne/s/cm(5); P = 0.0625).
Conclusion: After conversion, P(G) shows a tendency to increase and RFR decreases significantly-characteristics of hyperfiltration, which could possibly partially explain the increase of proteinuria. Therefore, the application of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers seems promising. To avoid hyperfiltration, conversion should be performed early when renal insufficiency is still moderate.
Similar articles
-
Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.Transplant Proc. 2009 Sep;41(7):2789-93. doi: 10.1016/j.transproceed.2009.07.094. Transplant Proc. 2009. PMID: 19765436
-
Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.Transplant Proc. 2011 Jul-Aug;43(6):2187-90. doi: 10.1016/j.transproceed.2011.06.055. Transplant Proc. 2011. PMID: 21839229
-
Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.Pediatr Transplant. 2006 Jun;10(4):474-8. doi: 10.1111/j.1399-3046.2006.00503.x. Pediatr Transplant. 2006. PMID: 16712606
-
Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.Nephrol Dial Transplant. 2006 Mar;21(3):562-8. doi: 10.1093/ndt/gfi336. Epub 2005 Dec 16. Nephrol Dial Transplant. 2006. PMID: 16361278 Review. No abstract available.
-
[Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].Nephrol Ther. 2009 Dec;5 Suppl 6:S395-9. doi: 10.1016/S1769-7255(09)73432-7. Nephrol Ther. 2009. PMID: 20129452 Review. French.
Cited by
-
Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.Drug Saf. 2019 Jul;42(7):813-825. doi: 10.1007/s40264-019-00810-9. Drug Saf. 2019. PMID: 30868436 Review.
-
Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.J Korean Med Sci. 2014 Aug;29(8):1069-76. doi: 10.3346/jkms.2014.29.8.1069. Epub 2014 Jul 30. J Korean Med Sci. 2014. PMID: 25120315 Free PMC article. Clinical Trial.
-
Sirolimus-associated proteinuria and renal dysfunction.Drug Saf. 2006;29(12):1153-61. doi: 10.2165/00002018-200629120-00006. Drug Saf. 2006. PMID: 17147461 Review.
-
Use of sirolimus in solid organ transplantation.Drugs. 2007;67(3):369-91. doi: 10.2165/00003495-200767030-00004. Drugs. 2007. PMID: 17335296 Review.
-
Renal cortex neuronal nitric oxide synthase in response to rapamycin in kidney transplantation.Nitric Oxide. 2008 Feb;18(1):80-6. doi: 10.1016/j.niox.2007.10.001. Epub 2007 Oct 12. Nitric Oxide. 2008. PMID: 17971307 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical